|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bruix J, Gores GJ and Mazzaferro V:
Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut.
63:844–855. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Torres HA, Vauthey JN, Economides MP,
Mahale P and Kaseb A: Hepatocellular carcinoma recurrence after
treatment with direct-acting antivirals: First, do no harm by
withdrawing treatment. J Hepatol. 65:862–864. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye
QH, Wang L, Zhou J, Qiu SJ, Li Y, et al: A decade's studies on
metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol.
130:187–196. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chapman BC, Paniccia A, Hosokawa PW,
Henderson WG, Overbey DM, Messersmith W, McCarter MD, Gleisner A,
Edil BH, Schulick RD, et al: Impact of Facility Type and Surgical
Volume on 10-Year Survival in Patients Undergoing Hepatic Resection
for Hepatocellular Carcinoma. J Am Coll Surg. 224:362–372. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yang J, Mani SA, Donaher JL, Ramaswamy S,
Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and
Weinberg RA: Twist, a master regulator of morphogenesis, plays an
essential role in tumor metastasis. Cell. 117:927–939. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hirohashi S and Kanai Y: Cell adhesion
system and human cancer morphogenesis. Cancer Sci. 94:575–581.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sugimachi K, Taguchi K, Aishima S, Tanaka
S, Shimada M, Kajiyama K, Sugimachi K and Tsuneyoshi M: Altered
expression of beta-catenin without genetic mutation in intrahepatic
cholangiocarcinoma. Mod Pathol. 14:900–905. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rhim AD, Mirek ET, Aiello NM, Maitra A,
Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK,
Vonderheide RH, et al: EMT and dissemination precede pancreatic
tumor formation. Cell. 148:349–361. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peinado H, Olmeda D and Cano A: Snail, Zeb
and bHLH factors in tumour progression: An alliance against the
epithelial phenotype? Nat Rev Cancer. 7:415–428. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ho IC and Pai SY: GATA-3 - not just for
Th2 cells anymore. Cell Mol Immunol. 4:15–29. 2007.PubMed/NCBI
|
|
12
|
Simon MC: Gotta have GATA. Nat Genet.
11:9–11. 1995. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hosoya T, Maillard I and Engel JD: From
the cradle to the grave: Activities of GATA-3 throughout T-cell
development and differentiation. Immunol Rev. 238:110–125. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Haraguchi T, Miyoshi H, Hiraoka K,
Yokoyama S, Ishibashi Y, Hashiguchi T, Matsuda K, Hamada T, Okawa
T, Shiba N, et al: GATA3 Expression Is a Poor Prognostic Factor in
Soft Tissue Sarcomas. PLoS One. 11:e01565242016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Engelsen IB, Stefansson IM, Akslen LA and
Salvesen HB: GATA3 expression in estrogen receptor alpha-negative
endometrial carcinomas identifies aggressive tumours with high
proliferation and poor patient survival. Am J Obstet Gynecol.
199:543.e1–7. 2008. View Article : Google Scholar
|
|
16
|
Peng H, Ke XX, Hu R, Yang L, Cui H and Wei
Y: Essential role of GATA3 in regulation of differentiation and
cell proliferation in SK-N-SH neuroblastoma cells. Mol Med Rep.
11:881–886. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ma L, Xue W and Ma X: GATA3 is
downregulated in osteosarcoma and facilitates EMT as well as
migration through regulation of slug. OncoTargets Ther.
11:7579–7589. 2018. View Article : Google Scholar
|
|
18
|
Yin G, Liu Z, Wang Y, Sun L, Wang L, Yao
B, Liu R, Chen T, Niu Y and Liu Q: ZNF503 accelerates
aggressiveness of hepatocellular carcinoma cells by down-regulation
of GATA3 expression and regulated by microRNA-495. Am J Transl Res.
11:3426–3437. 2019.PubMed/NCBI
|
|
19
|
Zheng Y, Wang DD, Wang W, Pan K, Huang CY,
Li YF, Wang QJ, Yuan SQ, Jiang SS, Qiu HB, et al: Reduced
expression of uroplakin 1A is associated with the poor prognosis of
gastric adenocarcinoma patients. PLoS One. 9:e930732014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cai X, Zhu H and Li Y: PKCζ, MMP-2 and
MMP-9 expression in lung adenocarcinoma and association with a
metastatic phenotype. Mol Med Rep. 16:8301–8306. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhao Y, Zhou FL, Li WP, Wang J and Wang
LJ: Slit2 Robo1 signaling promotes the adhesion, invasion and
migration of tongue carcinoma cells via upregulating matrix
metalloproteinases 2 and 9, and downregulating E cadherin. Mol Med
Rep. 14:1901–1906. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liao TT and Yang MH: Revisiting
epithelial-mesenchymal transition in cancer metastasis: The
connection between epithelial plasticity and stemness. Mol Oncol.
11:792–804. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mehra R, Varambally S, Ding L, Shen R,
Sabel MS, Ghosh D, Chinnaiyan AM and Kleer CG: Identification of
GATA3 as a breast cancer prognostic marker by global gene
expression meta-analysis. Cancer Res. 65:11259–11264. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Si W, Huang W, Zheng Y, Yang Y, Liu X,
Shan L, Zhou X, Wang Y, Su D, Gao J, et al: Dysfunction of the
reciprocal feedback loop between GATA3- and ZEB2-nucleated
repression programs contributes to breast cancer metastasis. Cancer
Cell. 27:822–836. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shan L, Li X, Liu L, Ding X, Wang Q, Zheng
Y, Duan Y, Xuan C, Wang Y, Yang F, et al: GATA3 cooperates with
PARP1 to regulate CCND1 transcription through modulating histone H1
incorporation. Oncogene. 33:3205–3216. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Takai M, Terai Y, Kawaguchi H, Ashihara K,
Fujiwara S, Tanaka T, Tsunetoh S, Tanaka Y, Sasaki H, Kanemura M,
et al: The EMT (epithelial-mesenchymal-transition)-related protein
expression indicates the metastatic status and prognosis in
patients with ovarian cancer. J Ovarian Res. 7:762014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wei S, Zhong L, Wang X and Zhang W: Low
expression of GATA3 promotes cell proliferation and metastasis in
gastric cancer. Cancer Manag Res. 9:769–780. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guan Y, Li W, Hou Z, Han Q, Lan P, Zhang
J, Tian Z and Zhang C: HBV suppresses expression of MICA/B on
hepatoma cells through up-regulation of transcription factors GATA2
and GATA3 to escape from NK cell surveillance. Oncotarget.
7:56107–56119. 2016. View Article : Google Scholar : PubMed/NCBI
|
